Our results suggest that therapeutic efforts to target the activity of DNAJB6 and related co-chaperones in synucleinopathies and poly-Q disorders may also be beneficial for c9FTD/ALS patients, potentially targeting both TDP-43 and poly-GA aggregation. This evidence concerns the gene DNAJB6 and synucleinopathy.